<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190107042264N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-27</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Ropivacaine against Ropivacaine and Dexmedetomidine on postoperative pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of ultrasound guided intercostal nerve block with ropivacaine against Ropivacaine and Dexmedetomidine on reduction of postoperative pain in patients undergoing thoracotomy: a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>74</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50925</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Using Research Randomizer(freely available at www.randomizer.org) 74 random numbers are generated. this unsorted series of numbers are then used to assign coded drugs to patients, Blinding description: After obtaining a series of unsorted random numbers from the website, the numbers are used to divide consecutive patients into two groups. This data is then given to the anesthesiologist in charge of the study. This specialist, who is aware of patient assignments, Prepares study medications for injection in a transparent syringe, labeled with the code of each patient and provides them to a second anesthesiologist. this second anesthesiologist, who is unaware of the contents of the syringe then puts patients, who are unaware of the used medications, under intercostal nerve block. Patients are then transferred to the intensive care unit and monitored. Here, the patient data is collected in coded forms by the data collection team, who are unaware of patient assignment to groups. This information is provided to the statistical analyzer in numbered forms along with the information related to the assignment to the groups for statistical analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>Post Thoracotomy Pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: At the end of the thoracotomy operation, after extubation in recovery and after hemodynamic stability, Intercostal nerve block under ultrasound guidance (model: M7 made by MindRay company, China) is performed by Pain Fellowship. The intercostal block is performed in supine position and along the posterior axillary line. The ultrasound probe is placed sagitally and after identifying the External, Internal and innermost intercostal muscles, using the Quinke Spinal Needle No. 22 (made by Dr. Japan, Japan), Injection for the intercostal nerve block is done in one space above and two spaces below the surgical incision site. In the Intervention Group Ropivacaine (5 cc of 0.25% solution; made by Molteni Farmaceutici, Italy) plus dexmedetomidine 0.5 mcg per kilogram body weight (Medonex, Exir Pharmaceutical Co., Iran) is used, Divided between the three spaces. Intervention 2: Control group: At the end of thoracotomy and after extubation and hemodynamic stability, in the recovery room, intercostal nerve block under ultrasound guidance (model: M-7 made by Mindray, China) is performed by pain fellowship. The intercostal block is performed in the supine position and along the posterior axillary line. The ultrasound probe is placed sagittally and after identifying the External, Internal and innermost intercostal muscles, using the Quinke Spinal Needle No. 22 (made by Dr. Japan, Japan) Injection for the intercostal nerve block is done in one space above and two spaces below the surgical incision site. In the control group, Ropivacaine (5 cc of 0.25% solution; made by Molteni Farmaceutici, Italy), is used, Divided between the three spaces.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No Specific Plan of action exists regarding the matter</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kamran Mahmoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital - Shahid Ahvazian Street - Azadegan Street</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673111</zip>
        <telephone>+98 61 3222 2114</telephone>
        <email>mahmoudi-k@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kamran Mahmoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital - Shahid Ahvazian Street - Azadegan Street</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673111</zip>
        <telephone>+98 61 3222 2114</telephone>
        <email>mahmoudi-k@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>American Society of Anesthesiologists physical status Class I, II or III
Body Mass Index less than 40
No History of Alcohol or Drug abuse
Not pregnant/Breastfeeding
No history of coagulation problems or use of anticoagulants
Ejection Fraction more than 30%
No history of cardiac conduction block (except for first-degree cardiac block and controlled atrial fibrillation)
No acute or chronic hepatitis
No history of psychiatric illness
No Need for renal supplementation or a history of kidney failure
No Known Neuropathy</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hypersensitivity to study drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.12</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute post-thoracotomy pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: At the end of the thoracotomy operation, after extubation in recovery and after hemodynamic stability, Intercostal nerve block under ultrasound guidance (model: M7 made by MindRay company, China) is performed by Pain Fellowship. The intercostal block is performed in supine position and along the posterior axillary line. The ultrasound probe is placed sagitally and after identifying the External, Internal and innermost intercostal muscles, using the Quinke Spinal Needle No. 22 (made by Dr. Japan, Japan), Injection for the intercostal nerve block is done in one space above and two spaces below the surgical incision site. In the Intervention Group Ropivacaine (5 cc of 0.25% solution; made by Molteni Farmaceutici, Italy) plus dexmedetomidine 0.5 mcg per kilogram body weight (Medonex, Exir Pharmaceutical Co., Iran) is used, Divided between the three spaces.</i_keyword>
      <i_keyword>Control group: At the end of thoracotomy and after extubation and hemodynamic stability, in the recovery room, intercostal nerve block under ultrasound guidance (model: M-7 made by Mindray, China) is performed by pain fellowship. The intercostal block is performed in the supine position and along the posterior axillary line. The ultrasound probe is placed sagittally and after identifying the External, Internal and innermost intercostal muscles, using the Quinke Spinal Needle No. 22 (made by Dr. Japan, Japan) Injection for the intercostal nerve block is done in one space above and two spaces below the surgical incision site. In the control group, Ropivacaine (5 cc of 0.25% solution; made by Molteni Farmaceutici, Italy), is used, Divided between the three spaces.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Immediately after return to Surgical Intensive Care Unit (ICU) from post surgical recovery, then again after 6, 12, 24 and 48 hours from return to surgical ICU. Method of measurement: Visual Analog Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic Blood Pressure. Timepoint: Immediately after return to Surgical Intensive Care Unit (ICU) from post surgical recovery, then again after 6, 12, 24 and 48 hours from return to surgical ICU. Method of measurement: Aneroid Sphygmomanometer.</sec_outcome>
      <sec_outcome>Pulse Rate. Timepoint: Immediately after return to Surgical Intensive Care Unit (ICU) from post surgical recovery, then again after 6, 12, 24 and 48 hours from return to surgical ICU. Method of measurement: Pulse Oxymeter.</sec_outcome>
      <sec_outcome>Oxygen Saturation. Timepoint: Immediately after return to Surgical Intensive Care Unit (ICU) from post surgical recovery, then again after 6, 12, 24 and 48 hours from return to surgical ICU. Method of measurement: Pulse Oxymeter.</sec_outcome>
      <sec_outcome>Diastolic Blood Pressure. Timepoint: Immediately after return to Surgical Intensive Care Unit (ICU) from post surgical recovery, then again after 6, 12, 24 and 48 hours from return to surgical ICU. Method of measurement: Aneroid Sphygmomanometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-10</approval_date>
        <contact_name>Ethics committee of Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Esfand Street, Golestan, Ahvaz, Iran Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
